Showing results (541-550 of 576) with videos related to

Sort By:
Pageof 58
Infectious Diseases (London, England)|July 1, 2023
Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpointsBurcu Isler, Cansel Vatansever, Berna Özer, et al.
International Journal of Antimicrobial Agents|August 8, 2017
Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT studyPatrick N A Harris, M Diletta Pezzani, Belén Gutiérrez-Gutiérrez, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 18, 2022
Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic settingBurcu Isler, Berna Özer, Güle Çınar, et al.
The Lancet. Infectious Diseases|April 27, 2017
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort studyBelén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2016
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort studyBelén Gutiérrez-Gutiérrez, Robert A Bonomo, Yehuda Carmeli, et al.
Diagnostic Microbiology and Infectious Disease|July 17, 2022
Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolatesBurcu Isler, Cansel Vatansever, Berna Özer, et al.
Infection Control and Hospital Epidemiology|April 6, 2018
Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniaeOded Scheuerman, Vered Schechner, Yehuda Carmeli, et al.
The Lancet. Infectious Diseases|October 9, 2025
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trialDavid L Paterson, Helmi Sulaiman, Po-Yu Liu, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2026
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas studyLee S Gottesdiener, Yixuan Li, Kerryl E Greenwood-Quaintance, et al.
JAMA|September 13, 2018
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical TrialPatrick N A Harris, Paul A Tambyah, David C Lye, et al.
Pageof 58